For example, if you add 2mL of BAC water to 10mg of Retatrutide, each 0.1mL contains 0.5mg of the peptide
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Please consult your doctor if these side effects persist for a longer duration
Proper reconstitution technique prevents contamination and preserves peptide stability across the dosing period
Balanced conclusion: promising metabolic findings in preclinical studies not a proven human weight-loss therapy Q7: Does it suppress appetite
